Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 13/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.38 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.38 |
| ▸ | TRIB2 | Q92519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135807 | 0.98 | PRMT3 (0.47) | PRMT3MMP1MMP13MMP9ADAM17 | |
| SCHEMBL10135623 | 0.87 | GPR119 (0.47) | PRMT3CYP2C9HRH3CHRM2PIM1 | |
| SCHEMBL10135633 | 0.87 | GPR119 (0.47) | PRMT3CYP2C9HRH3CHRM2PIM1 | |
| SCHEMBL10135673 | 0.85 | GPR119 (0.47) | PRMT3CYP2C9HRH3CHRM2PIM1 | |
| SCHEMBL10135798 | 0.84 | PRMT3 (0.52) | PRMT3SIGMAR1 | |
| SCHEMBL10135733 | 0.84 | GPR119 (0.46) | PRMT3CYP2C9 | |
| SCHEMBL10135696 | 0.84 | GPR119 (0.46) | PRMT3CYP2C9 | |
| SCHEMBL10135809 | 0.84 | PRMT3 (0.48) | PRMT3HRH3CHRM2PIM1ACHE | |
| SCHEMBL10135808 | 0.83 | PRMT3 (0.49) | PRMT3CYP2C9HRH3CHRM2PIM1 | |
| SCHEMBL10135802 | 0.82 | PRMT3 (0.43) | PRMT3HRH3CHRM2PIM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | PRMT3 237/4885MMP1 4000/4885MMP13 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.